Meds A-Z
Trilostane
Detailed information about Trilostane
Pet Owner Quick Guide
Start here: what this medicine is for, what it does, and when it's usually needed.
Usually used for:
For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.
What it does:
Used to treat hyperadrenocorticism (Cushing’s disease) in dogs by inhibiting cortisol production. Requires regular monitoring via ACTH stimulation tests and electrolyte checks.
When it's needed:
Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.
Call your vet sooner if you notice:
- Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.
Commonly reported reactions:
- (2 reports)
- (2 reports)
- (1 reports)
What to ask your vet today:
- Is this medicine the right fit for my pet’s current symptoms?
- Which warning signs mean I should call back right away?
- How should I handle missed doses or refusal to take the medicine?
Trilostane
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Dog
Manufacturer: MSK
Quick Facts
Official label facts first, then secondary summaries. Marketing content is separated below.
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141291 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source
Warnings / Contraindications
Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.
- High: Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source
Adverse Reactions
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Tap or hover a reaction to see what it means in plain language.
Most Reported Reactions
| Reaction | Cases | Species | Serious cases |
|---|---|---|---|
| 2 | Cat, Dog | 2 | |
| 2 | Cat, Dog | 2 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 | |
| 1 | Dog | 1 | |
| 1 | Cat | 1 |
Species coverage: Cat (17) Dog (15)
View detailed reaction table
| Reaction | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Dog | Non-serious | - | 1 |
- https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-055018
Storage & Handling
Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.
Documents
Official label facts are separated from secondary summaries.
Official documents: 4 • Secondary summaries: 0
- UCM173123.pdf · FOI
- UCM508381.pdf · FOI
- VETORYL N141291C0048.pdf · Labeling
- VETORYL® CAPSULES · SPL
No source yet.
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/856 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/855 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/914 · document · Labeling
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2017/VETORYL%C2%AE%20CAPSULES · document · SPL
Promotional Materials (Marketing)
This content is marketing material and not clinical guidance.
No marketing assets are linked yet.
No source yet.
Technical appendix (vet reference)
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
At a Glance
Quick facts and links to official labeling and safety signals.
- Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 7:40 PM UTC
-
Animal Drugs @ FDA:
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Applications/products are imported from FDA export data.
-
Animal Drugs @ FDA previews:
Source FDA
| Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
-
Animal Drug Product Listing Directory (NDC):
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
- openFDA reaction terms: Source FDA openFDA | Refreshed Feb 16, 2026, 11:01 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed Feb 12, 2026, 10:41 PM UTC
Counseling and Monitoring Highlights
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
- Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors. (Contraindication, High)
Identifiers & Packages
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 17033-105-30 | 17033 | - | |
| 17033-110-30 | 17033 | - | |
| 17033-111-30 | 17033 | - | |
| 17033-112-30 | 17033 | - | |
| 17033-130-30 | 17033 | - | |
| 17033-160-30 | 17033 | - | |
| 58597-7038-6 | 58597 | - | |
| 62157-361-01 | 62157 | - | |
| 62157-401-01 | 62157 | - | |
| 62157-556-01 | 62157 | - | |
| 62157-557-01 | 62157 | - | |
| 62157-560-01 | 62157 | - | |
| 62157-596-01 | 62157 | - | |
| 62157-927-01 | 62157 | - | |
| 62991-2736-1 | 62991 | - | |
| 62991-2736-2 | 62991 | - | |
| 62991-2736-3 | 62991 | - | |
| 62991-2736-4 | 62991 | - | |
| 62991-2736-5 | 62991 | - | |
| 63732-2018-4 | 63732 | - |
Enriched Documents
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
-
VETORYL N141291C0048.pdf
• Official label • Official
• May 20, 2024
FDA official labeling for application 141291
-
UCM508381.pdf
• FOI summary • Official
• May 20, 2024
FDA FOI summary for application 141291
-
UCM173123.pdf
• FOI summary • Official
• May 20, 2024
FDA FOI summary for application 141291
Data Sources & Revision History
Every non-trivial field is expected to include provenance and update timestamps.
- overdose_info: Overdose can cause acute adrenal insufficiency with signs of collapse, severe weakness, and gastrointestinal upset. Immediate emergency treatment with IV fluid… (Clinical, 2026-02-12)
- storage_handling: Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and … (Clinical, 2026-02-12)
- contraindications: Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE … (Official, 2026-02-12)
- side_effects: Common side effects include decreased appetite, vomiting, diarrhea, and lethargy; may lead to an Addisonian crisis if cortisol is overly suppressed. (Official, 2026-02-12)
- usage: Used to treat hyperadrenocorticism (Cushing’s disease) in dogs by inhibiting cortisol production. Requires regular monitoring via ACTH stimulation tests and el… (Official, 2026-02-12)
- side_effects updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
- contraindications updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
- usage updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
FDA Products & Applications (Animal Drugs @ FDA)
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
VETORYL® CAPSULES
RX
Trilostane
Capsule
• Oral
|
Dechra, Ltd. | NADA 141-291 | Approved | May 20, 2024 |
Data source: FDA Animal Drugs @ FDA (public search export).
What It's For (FDA Label Highlights)
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
Composition / specifications
For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.
FDA page: Open in Animal Drugs @ FDA
Official Documents (FDA)
Direct links to FDA-hosted PDFs and SPL packages (when available).
-
FOI UCM173123.pdf
Summary
This supplement provides for the addition of a 10 mg capsule size. -
FOI UCM508381.pdf
Summary
For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. -
Labeling VETORYL N141291C0048.pdf
- VETORYL® CAPSULES (ZIP)
FDA page: Open in Animal Drugs @ FDA
Usage
Used to treat hyperadrenocorticism (Cushing’s disease) in dogs by inhibiting cortisol production. Requires regular monitoring via ACTH stimulation tests and electrolyte checks.
Source: FDA Animal Drugs @ FDA • Reference
Contraindications
Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.
Side Effects
Common side effects include decreased appetite, vomiting, diarrhea, and lethargy; may lead to an Addisonian crisis if cortisol is overly suppressed.
Source: FDA openFDA • Reference
Top Reported Reactions (openFDA)
Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Adverse Event Case Summaries (openFDA)
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Dog, ['Terrier - Bull - American Pit', 'Dog (unknown)'], Female, 8 month, 32.205 kilogram • Drug: MSK, Unassigned, Oral, Dose: 60 Milligram per animal, Frequency: 1 per day • Reactions: Head twitching, Abnormal movement NOS, Injection site tenderness • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-055018
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 8.00 Month
- Weight: 32.205 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Unassigned
- Dose: 60 Milligram per animal
- Frequency: 1 per day
Dog, Dog (unknown), Female, 14 year, 17.3 kilogram • Drug: MSK, Capsule, Dose: 10 Milligram per animal, Frequency: 12 per hour • Reactions: Collapse NOS, Death • Outcome: Died
- Report ID: USA-USFDACVM-2025-US-055856
- Serious AE: Yes
- Treated For AE: No
- Sex: Female
- Age: 14.00 Year
- Weight: 17.300 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Form: Capsule
- Dose: 10 Milligram per animal
- Frequency: 12 per hour
Dog, ['Pug', 'Crossbred Canine/dog'], Female, 14 year, 10 kilogram • Drug: MSK, Capsule, Oral, Dose: 15 Milligram per animal, Frequency: 24 per hour • Reactions: Diarrhea, Vomiting, Elevated blood urea nitrogen, Appetite loss, Hyperkalaemia… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-055954
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Female
- Age: 14.00 Year
- Weight: 10.000 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Capsule
- Dose: 15 Milligram per animal
- Frequency: 24 per hour
Dog, Shih Tzu, Female, 7 year, 7.9 kilogram • Drug: MSK, Capsule, Oral, Dose: 5 Milligram per animal, Frequency: 12 per hour • Reactions: Elevated serum alkaline phosphatase • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-055962
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 7.00 Year
- Weight: 7.900 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Capsule
- Dose: 5 Milligram per animal
- Frequency: 12 per hour
Dog, Shiba Inu, Female, 6 year, 15 kilogram • Drug: MSK, Capsule, Oral, Dose: 40 Milligram per animal, Frequency: 24 per hour • Reactions: Elevated serum alkaline phosphatase, Hypocortisolaemia, Weight loss, Muscle atrophy, General illness • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-055961
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 6.00 Year
- Weight: 15.000 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Capsule
- Dose: 40 Milligram per animal
- Frequency: 24 per hour
Dog, Terrier - Boston, Male, 10 year, 11.36 kilogram • Drug: MSK, Capsule, Oral, Dose: 20 Milligram per animal, Frequency: 24 per hour • Reactions: Vomiting, Tiredness (lethargy), Decreased appetite • Outcome: Recovered/Normal
- Report ID: USA-USFDACVM-2025-US-055963
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 10.00 Year
- Weight: 11.360 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Capsule
- Dose: 20 Milligram per animal
- Frequency: 24 per hour
Cat, Himalayan, Male, 12.5 year, 5.806 kilogram • Drug: MSK, Capsule, Oral, Dose: 5 Milligram per animal, Frequency: 12 per hour • Reactions: Weight loss, Unresponsive to stimuli, Hypernatremia, Decreased appetite, Anisocoria… • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2021-US-023707
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 12.50 Year
- Weight: 5.806 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Capsule
- Dose: 5 Milligram per animal
- Frequency: 12 per hour
Cat, Domestic Shorthair, Male, 12 year, 8.13 kilogram • Drug: MSK, Capsule, Oral, Dose: 10 Milligram per animal, Frequency: 24 per hour • Reactions: Hyperglycaemia, Diabetes mellitus, Renal failure, Decreased appetite, Weakness… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2021-US-020960
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 12.00 Year
- Weight: 8.130 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Capsule
- Dose: 10 Milligram per animal
- Frequency: 24 per hour
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Overdose Information
Overdose can cause acute adrenal insufficiency with signs of collapse, severe weakness, and gastrointestinal upset. Immediate emergency treatment with IV fluids and corticosteroids is required.
Storage & Handling
Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.
Share Your Thoughts
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.